Mohammad Haris Ali
Research Subjects
Mohammad Haris Ali has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Talha
Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Pakistan
7 shared publications - Hamza Irfan
Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Pakistan
4 shared publications Muhammad Talha
Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan
3 shared publications- Syed Ahmed Shahzaeem Hussain
Department of ENT, Shaikh Zayed Hospital, Shaikh Zayed Medical Complex, Lahore, Pakistan
2 shared publications - Ahmad Zain
Department of Internal Medicine, UCHealth Parkview Medical Center, Pueblo, CO
1 shared publication Al Haisbuzzaman
Department of Medicine, Niramoy Hospital, Panchagarh, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 30 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4014-4016
Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial
Alpha-1 antitrypsin deficiency (AATD) is a prevalent autosomal recessive disorder affecting approximately 3 million people worldwide, caused by mutations in the SERPINA1 gene leading to low alpha-1 antitrypsin (AAT) levels. This deficiency predisposes individuals to chronic obstructive pulmonary disease, bronchiectasis, neonatal cholestasis, and liver cirrhosis. The most common pathogenic mutation, PI*ZZ allele, produces misfolded Z-AAT protein accumulating in hepatocytes. Currently, there are no specific treatments for AATD-related liver disease, with management focusing on preventing complications. Fazirsiran, an investigational RNA interference therapeutic, targets hepatocytes to reduce Z-AAT synthesis. Preclinical studies and an open-label phase 2 trial showed promising results. The subsequent phase 2 SEQUOIA trial, a randomized controlled study, evaluated Fazirsiran’s efficacy and safety in 40 PiZZ homozygous patients. Results demonstrated significant dose-dependent reductions in serum Z-AAT levels (−61% to −94%) and liver Z-AAT concentrations, improved liver histopathology, and a favorable safety profile. These findings support Fazirsiran’s potential as a therapeutic option for AATD-associated liver disease.
- 30 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4014-4016
Open AccessFazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial
Alpha-1 antitrypsin deficiency (AATD) is a prevalent autosomal recessive disorder affecting approximately 3 million people worldwide, caused by mutations in the SERPINA1 gene leading to low alpha-1 antitrypsin (AAT) levels. This deficiency predisposes individuals to chronic obstructive pulmonary disease, bronchiectasis, neonatal cholestasis, and liver cirrhosis. The most common pathogenic mutation, PI*ZZ allele, produces misfolded Z-AAT protein accumulating in hepatocytes. Currently, there are no specific treatments for AATD-related liver disease, with management focusing on preventing complications. Fazirsiran, an investigational RNA interference therapeutic, targets hepatocytes to reduce Z-AAT synthesis. Preclinical studies and an open-label phase 2 trial showed promising results. The subsequent phase 2 SEQUOIA trial, a randomized controlled study, evaluated Fazirsiran’s efficacy and safety in 40 PiZZ homozygous patients. Results demonstrated significant dose-dependent reductions in serum Z-AAT levels (−61% to −94%) and liver Z-AAT concentrations, improved liver histopathology, and a favorable safety profile. These findings support Fazirsiran’s potential as a therapeutic option for AATD-associated liver disease.
- 13 November 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials
- 13 November 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Safety and efficacy of IL-17 inhibitors in hidradenitis suppurativa: an updated systematic review and meta-analysis including the BE-HEARD trials
- Open Access
- 16 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7072-7081
Efficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly concerning due to its rising prevalence. It encompasses conditions from simple steatosis to severe nonalcoholic steatohepatitis (NASH), posing risks such as fibrosis, cirrhosis, or hepatocellular carcinoma if untreated. This systematic review and meta-analysis aims to assess aldafermin, an FGF19 analog, for efficacy and safety in NASH patients. Methods: Eligible studies were identified by searching PubMed, Cochrane Library, and Google Scholar, resulting in 1115 studies. Three RCTs were included. The risk of bias was assessed using the Cochrane Risk of Bias tool, and data synthesis utilized Review Manager software. The certainty of evidence was evaluated with the GRADE approach. Results: In the 3 mg dose group, aldafermin significantly improved various parameters. The ELF score decreased notably (pooled MD: −0.46, 95% CI: −0.64 to −0.28; P P P =0.02). Furthermore, significant reductions were noted in absolute AST levels (pooled MD: −13.40, 95% CI: −18.66 to −8.14; P P <0.00001), suggesting improved liver function. Conclusion: The meta-analysis indicates that aldafermin, particularly, the 3 mg dose, shows significant efficacy in improving liver histology and biochemical markers in NASH patients compared to placebo, along with a satisfactory safety profile.
- 16 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7072-7081
Open AccessEfficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly concerning due to its rising prevalence. It encompasses conditions from simple steatosis to severe nonalcoholic steatohepatitis (NASH), posing risks such as fibrosis, cirrhosis, or hepatocellular carcinoma if untreated. This systematic review and meta-analysis aims to assess aldafermin, an FGF19 analog, for efficacy and safety in NASH patients. Methods: Eligible studies were identified by searching PubMed, Cochrane Library, and Google Scholar, resulting in 1115 studies. Three RCTs were included. The risk of bias was assessed using the Cochrane Risk of Bias tool, and data synthesis utilized Review Manager software. The certainty of evidence was evaluated with the GRADE approach. Results: In the 3 mg dose group, aldafermin significantly improved various parameters. The ELF score decreased notably (pooled MD: −0.46, 95% CI: −0.64 to −0.28; P P P =0.02). Furthermore, significant reductions were noted in absolute AST levels (pooled MD: −13.40, 95% CI: −18.66 to −8.14; P P <0.00001), suggesting improved liver function. Conclusion: The meta-analysis indicates that aldafermin, particularly, the 3 mg dose, shows significant efficacy in improving liver histology and biochemical markers in NASH patients compared to placebo, along with a satisfactory safety profile.
- Open Access
- 6 August 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (8) , e2294
Mirikizumab: A promising breakthrough in Crohn's disease treatment
Introduction: Crohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous “skip lesions” throughout the gastrointestinal tract. With a prevalence of 100–300 cases per 100,000 individuals, CD is most common in Western Europe and North America. Symptoms include abdominal pain, diarrhea, fever, weight loss, and anemia, with severe cases leading to complications such as perianal abscesses and cutaneous fistulas. Treatment involves pharmaceutical interventions, bowel rest, and sometimes surgery, with biological therapies like ustekinumab and mirikizumab gaining prominence.Clinical Trials: The VIVID‐1 trial assessed mirikizumab in patients with moderately to severely active CD. By Week 12, mirikizumab significantly outperformed placebo in clinical response (45.4% vs. 19.6%, p < 0.000001). By Week 52, it showed higher clinical remission rates (54.1% vs. 19.6%) and demonstrated non‐inferiority to ustekinumab in clinical remission (p = 0.51). The SEQUENCE study compared risankizumab to ustekinumab, with risankizumab showing superior reductions in inflammatory markers and higher biologic remission rates at Weeks 8, 24, and 48. Both treatments had similar safety profiles, with common adverse events including COVID‐19, anemia, and headache.Conclusion: Mirikizumab, based on the VIVID‐1 trial outcomes, is a promising addition to CD therapy. It demonstrated significant clinical responses and remission rates, warranting further research on its long‐term efficacy and safety. Updating professional guidelines and addressing affordability will ensure broader access and improved management of CD.
- 6 August 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (8) , e2294
Open AccessMirikizumab: A promising breakthrough in Crohn's disease treatment
Introduction: Crohn's disease (CD) is a chronic, progressive inflammatory bowel disorder characterized by persistent inflammation and noncontiguous “skip lesions” throughout the gastrointestinal tract. With a prevalence of 100–300 cases per 100,000 individuals, CD is most common in Western Europe and North America. Symptoms include abdominal pain, diarrhea, fever, weight loss, and anemia, with severe cases leading to complications such as perianal abscesses and cutaneous fistulas. Treatment involves pharmaceutical interventions, bowel rest, and sometimes surgery, with biological therapies like ustekinumab and mirikizumab gaining prominence.Clinical Trials: The VIVID‐1 trial assessed mirikizumab in patients with moderately to severely active CD. By Week 12, mirikizumab significantly outperformed placebo in clinical response (45.4% vs. 19.6%, p < 0.000001). By Week 52, it showed higher clinical remission rates (54.1% vs. 19.6%) and demonstrated non‐inferiority to ustekinumab in clinical remission (p = 0.51). The SEQUENCE study compared risankizumab to ustekinumab, with risankizumab showing superior reductions in inflammatory markers and higher biologic remission rates at Weeks 8, 24, and 48. Both treatments had similar safety profiles, with common adverse events including COVID‐19, anemia, and headache.Conclusion: Mirikizumab, based on the VIVID‐1 trial outcomes, is a promising addition to CD therapy. It demonstrated significant clinical responses and remission rates, warranting further research on its long‐term efficacy and safety. Updating professional guidelines and addressing affordability will ensure broader access and improved management of CD.
- 19 March 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101400
The Role of Hepatic Stellate Cells and the Gas6/Axl Axis in Liver Fibrosis and Hepatocellular Carcinoma
- 19 March 2024
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 14 (5) , 101400
The Role of Hepatic Stellate Cells and the Gas6/Axl Axis in Liver Fibrosis and Hepatocellular Carcinoma
- Open Access
- 15 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2951-2962
Evaluation of non-invasive diagnostic tools for diarrhea: a systematic review of point-of-care tests and biomarkers
Background: Diarrhea is a prevalent condition affecting millions worldwide. However, current standard diagnostic methods have many drawbacks. This review examines various non-invasive point-of-care (POC) tests and biomarkers aiding rapid diagnosis of diarrhea from different causes. Methods: PubMed, PubMed Central, ScienceDirect, Cochrane Library, and Google Scholar were searched from 2013 to present for relevant literature. Two reviewers independently assessed included studies’ quality using the Critical Appraisal Skills Programme (CASP) checklist. Results: The search yielded 1453 studies, of which 39 were included after screening and applying eligibility criteria. Polymerase chain reaction (PCR) was the POC test in 25 studies, providing consistent sensitivity and specificity. For biomarkers, C-reactive protein (CRP), fecal calprotectin, and procalcitonin offered high sensitivity and specificity for conditions like acute pediatric diarrhea, microscopic colitis, and inflammatory diarrhea, respectively. Conclusion: PCR proved the ideal POC test for rapid diarrhea diagnosis, while the procalcitonin biomarker helps differentiate inflammatory from non-inflammatory diarrhea. Other reviewed tools also demonstrated promising diagnostic performance, though improvements in sensitivity, specificity, and usability are still needed.
- 15 March 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2951-2962
Open AccessEvaluation of non-invasive diagnostic tools for diarrhea: a systematic review of point-of-care tests and biomarkers
Background: Diarrhea is a prevalent condition affecting millions worldwide. However, current standard diagnostic methods have many drawbacks. This review examines various non-invasive point-of-care (POC) tests and biomarkers aiding rapid diagnosis of diarrhea from different causes. Methods: PubMed, PubMed Central, ScienceDirect, Cochrane Library, and Google Scholar were searched from 2013 to present for relevant literature. Two reviewers independently assessed included studies’ quality using the Critical Appraisal Skills Programme (CASP) checklist. Results: The search yielded 1453 studies, of which 39 were included after screening and applying eligibility criteria. Polymerase chain reaction (PCR) was the POC test in 25 studies, providing consistent sensitivity and specificity. For biomarkers, C-reactive protein (CRP), fecal calprotectin, and procalcitonin offered high sensitivity and specificity for conditions like acute pediatric diarrhea, microscopic colitis, and inflammatory diarrhea, respectively. Conclusion: PCR proved the ideal POC test for rapid diarrhea diagnosis, while the procalcitonin biomarker helps differentiate inflammatory from non-inflammatory diarrhea. Other reviewed tools also demonstrated promising diagnostic performance, though improvements in sensitivity, specificity, and usability are still needed.
- Open Access
- 4 March 2024
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 3 (1) , 1-3
Palovarotene approved as first treatment for fibrodysplasia ossificans progressiva (FOP)
- 4 March 2024
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 3 (1) , 1-3
Open AccessPalovarotene approved as first treatment for fibrodysplasia ossificans progressiva (FOP)
- 21 January 2024
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 36 (2-3) , 270-271
From Bangladesh to Pakistan: Tracking the Regional Surge in Conjunctivitis Cases
- 21 January 2024
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 36 (2-3) , 270-271
From Bangladesh to Pakistan: Tracking the Regional Surge in Conjunctivitis Cases
- 11 January 2024
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 36 (2-3) , 268-269
Emerging Threat: Crimean-Congo Hemorrhagic Fever in Balochistan, Pakistan
- 11 January 2024
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 36 (2-3) , 268-269
Emerging Threat: Crimean-Congo Hemorrhagic Fever in Balochistan, Pakistan
- 10 October 2023
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 35 (8) , 555-556
A Lingering Threat of Polio in Pakistan: A 2023 Update
- 10 October 2023
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 35 (8) , 555-556
A Lingering Threat of Polio in Pakistan: A 2023 Update